We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TransCode Therapeutics Inc | NASDAQ:RNAZ | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.3608 | -43.52% | 0.4682 | 0.4682 | 0.4699 | 0.84 | 0.781 | 0.829 | 419,953 | 00:59:10 |
| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Placement agent fees(1)
|
| | | $ | | | | | $ | | | ||
Proceeds to us, before expenses(2)
|
| | | $ | | | | | $ | | |
| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-iii | | | |
| | | | S-iv | | | |
| | | | S-1 | | | |
| | | | S-9 | | | |
| | | | S-13 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-17 | | | |
Dilution | | | | | S-23 | | |
| | | | S-24 | | | |
| | | | S-27 | | | |
| | | | S-27 | | | |
| | | | S-27 | | | |
| | | | S-28 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 15 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 25 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Historical net tangible book value per share as of March 31, 2024
|
| | | $ | 0.79 | | | | |||||
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | | | | ||||||
|
As adjusted net tangible book value per share as of March 31, 2024, after giving effect to
this offering |
| | | | | | | | | $ | | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | | | |
| | |
Per Share of
Common Stock |
| |
Per Pre-funded
Warrant |
| |
Total
|
| |||||||||
Offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Placement agent commissions (7.0%)
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds, before expense, to us
|
| | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 15 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 25 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 28 | | |
1 Year TransCode Therapeutics Chart |
1 Month TransCode Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions